Literature DB >> 11938850

[Endoscopic nasal surgery in treatment of nasopharyngeal angiofibroma].

D Han1, X Chen, J Wang.   

Abstract

OBJECTIVE: To avoid complications of the routine surgeries for nasopharyngeal angiofibroma.
METHODS: Endoscopic nasal surgery and other new techniques including controlled-hypotension anesthesia and preoperative feeding artery embolism had been used. From April 1996 to September 1997 eight young male patients with diagnosis of nasopharyngeal angiofibroma were treated by endoscopic sinus surgery. The average age was 16.6 years old. Six accepted preoperative embolism, seven accepted hypotension anesthesia.
RESULTS: No complications had occurred. Average intraoperative blood loss was 900 ml. All cases were followed for 1 to 20 months(mean 8 months). Recurrence was found in only one patient three months after operation. The recurrent rate was 12.5%.
CONCLUSION: The lesions limited to nasal and nasopharyngeal cavities and with sphnoid and ethmoid invasions can be removed by endoscopic nasal surgery. Endoscopic surgery has advantages in reducing complications and obtaining better post operative functions. Transnasal endoscopic examination is also necessary in the follow-up period. Other techniques such as CT, digital subtract angiography, preoperative feeding artery embolism and controlled-hypotension technique during anesthesia are beneficial.

Entities:  

Mesh:

Year:  1998        PMID: 11938850

Source DB:  PubMed          Journal:  Zhonghua Er Bi Yan Hou Ke Za Zhi        ISSN: 0412-3948


  2 in total

Review 1.  Imaging of lumps and bumps in the nose: a review of sinonasal tumours.

Authors:  Sudip Das; Claudia F E Kirsch
Journal:  Cancer Imaging       Date:  2005-12-09       Impact factor: 3.909

2.  Endoscopic surgery of nasopharyngeal angiofibroma.

Authors:  Lidiane Maria de Brito Macedo Ferreira; Erika Ferreira Gomes; Jorge Ferreira Azevedo; João Renato F Souza; Roberta de Paula Araújo; Adson Sales do Nascimento Rios
Journal:  Braz J Otorhinolaryngol       Date:  2006 Jul-Aug
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.